Press Release
February 20, 2013
DSM delivered growth across all clusters in 2012 excluding caprolactam. Nutrition represents more than 70% of total EBITDA and become high value, global business with attractive growth prospects across the full value chain.
Heerlen, NL, 20 Feb 2013 06:30 CET
Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “In the context of challenging macro-economic conditions, DSM delivered growth across all clusters in 2012, excluding caprolactam. Nutrition now represents more than 70% of total EBITDA and has become a high value, global business with attractive growth prospects across the full value chain.”
“The significant strategic progress we made during 2012 through our value creating acquisitions and the profit improvement initiatives we have taken leave us well positioned to achieve our long term objectives. In 2013 we will focus on the operational performance and integration of the acquisitions we completed in 2012 with special attention to capturing synergies. We expect strong EBITDA growth in 2013, moving towards €1.4 billion. The Board’s proposal to increase the dividend for the third consecutive year is testament to the stronger DSM we have built in recent years, with more stable growth and profitability going forward.”
| Q4 2012 | Q4 2011 | +/- | in € million | FY 2012 | FY 2011 | +/- |
|---|---|---|---|---|---|---|
| Continuing operations | ||||||
| 2,269 | 2,227 | 2% | Net sales | 9,131 | 9,048 | 1% |
| 243 | 293 | -17% | Operating profit before depreciation & amortization (EBITDA) | 1,109 | 1,296 | -14% |
| 204 | 193 | Nutrition | 793 | 735 | ||
| 13 | 11 | Pharma | 39 | 36 | ||
| 52 | 43 | Performance Materials | 280 | 293 | ||
| 14 | 79 | Polymer Intermediates | 129 | 380 | ||
| -9 | -17 | Innovation Center | -38 | -57 | ||
| -31 | -16 | Corporate Activities | -94 | -91 | ||
| 120 | 166 | -28% | Operating profit (EBIT) | 635 | 866 | -27% |
| Discontinued operations | ||||||
| Net sales | 145 | |||||
| Operating profit before depreciation & amortization (EBITDA) | 29 | |||||
| Operating profit (EBIT) | 29 | |||||
| Total DSM | ||||||
| 2,269 | 2,227 | 2% | Net sales | 9,131 | 9,193 | -1% |
| 243 | 293 | -17% | Operating profit before depreciation & amortization (EBITDA) | 1,109 | 1,325 | -16% |
| 75 | 118 | -36% | Net profit before exceptional items | 437 | 615 | -29% |
| -54 | -33 | Net result from exceptional items | -149 | 199 | ||
| 21 | 85 | -75% | Net profit | 288 | 814 | -65% |
| Net profit per share in €: | ||||||
| 0.43 | 0.71 | -39% | before exceptional items, continuing operations | 2.58 | 3.53 | -27% |
| 0.11 | 0.53 | -79% | including exceptional items, total DSM | 1.68 | 4.86 | -65% |
| core earnings per share | 2.78 | 3.66 | -24% |
You can find the press release in full, including financial statements, below.
Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com
Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com
+31 45 578 2420
+31 45 578 2864